Yayi Hou

Prof. Yayi Hou


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Theranostics
Verified
Journal Article
Open access
JRJing Ren
Jing Ren
LDLiang Ding
Liang Ding
DZDongya Zhang
Dongya Zhang
GSGuoping Shi
Guoping Shi
QXQianyun Xu
Qianyun Xu
YHYayi Hou
Yayi Hou
Long non-coding RNAs (lncRNAs) are involved in the pathology of various tumors, including colorectal cancer (CRC). The crosstalk between carcinoma- associated fibroblasts (CAFs) and cancer cells in the tumor microenvironment promotes tumor development and confers chemoresistance. In this study, we further investigated the underlying tumor-promoting roles of CAFs and the molecular mediators involved in these processes.

5 February 2017 in Stem Cells
Verified
Journal Article
Closed access
PDF file
YSYuxian Song
Yuxian Song
HDHuan Dou
Huan Dou
XLXiujun Li
Xiujun Li
XZXiaoyin Zhao
Xiaoyin Zhao
YLYi Li
Yi Li
YHYayi Hou
Yayi Hou

7 October 2013 in BMC Cancer
Verified
Journal Article
Open access
PDF file
KLKai-Hua Lu
Kai-Hua Lu
WLWei Li
Wei Li
XLXiang-Hua Liu
Xiang-Hua Liu
MSMing Sun
Ming Sun
MZMei-Ling Zhang
Mei-Ling Zhang
YHYayi Hou
Yayi Hou
Background: Long non-coding RNAs play an important role in tumorigenesis, hence, identification of cancer-associated lncRNAs and investigation of their biological functions and molecular mechanisms are important for understanding the development and progression of cancer. Recently, the downregulation of lncRNA MEG3 has been observed in various human cancers. However, its role in non-small cell lung cancer (NSCLC) is unknown. The aim of this study was to examine the expression pattern of MEG3 in NSCLC and to evaluate its biological role and clinical significance in tumor progression. Methods: Expression of MEG3 was analyzed in 44 NSCLC tissues and 7 NSCLC cell lines by qRT-PCR. Over-expression approaches were used to investigate the biological functions of MEG3 in NSCLC cells. Bisulfite sequencing was used to investigate DNA methylation on MEG3 expression. The effect of MEG3 on proliferation was evaluated by MTT and colony formation assays, and cell apoptosis was evaluated by Hoechst staining and Flow-cytometric analysis. NSCLC cells transfected with pCDNA-MEG3 were injection into nude mice to study the effect of MEG3 on tumorigenesis in vivo . Protein levels of MEG3 targets were determined by western blot analysis. Differences between groups were tested for significance using Student’s t-test (two-tailed). Results: MEG3 expression was decreased in non-small cell lung cancer (NSCLC) tumor tissues compared with normal tissues, and associated with advanced pathologic stage, and tumor size. Moreover, patients with lower levels of MEG3 expression had a relatively poor prognosis. Overexpression of MEG3 decreased NSCLC cells proliferation and induced apoptosis in vitro and impeded tumorigenesis in vivo. MDM2 and p53 protein levels were affected by MEG3 over-expression in vitro. Conclusions: Our findings indicate that MEG3 is significantly down-regulated in NSCLC tissues that could be affected by DNA methylation, and regulates NSCLC cell proliferation and apoptosis, partially via the activition of p53. Thus, MEG3 may represent a new marker of poor prognosis and is a potential therapeutic target for NSCLC intervention.

22 October 2012 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
HFHongye Fan
Hongye Fan
GZGuangfeng Zhao
Guangfeng Zhao
LLLiu Liu
Liu Liu
FLFei Liu
Fei Liu
WGWei Gong
Wei Gong
YHYayi Hou
Yayi Hou

13 January 2018 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
LDLiang Ding
Liang Ding
JRJing Ren
Jing Ren
DZDongya Zhang
Dongya Zhang
YLYi Li
Yi Li
XHXiaofeng Huang
Xiaofeng Huang
YHYayi Hou
Yayi Hou
Stromal carcinoma-related fibroblasts (CAFs) are the main type of non-immune cells in the tumor microenvironment (TME). CAFs interact with cancer cells to promote tumor proliferation. Long non-coding RNAs (lncRNAs) are known to regulate cell growth, apoptosis and metastasis of cancer cells, but their role in stromal cells is unclear. Using RNA sequencing, we identified a stromal lncRNA signature during the transformation of CAFs from normal fibroblasts (NFs) in oral squamous cell carcinoma (OSCC). We uncovered an uncharacterized lncRNA, FLJ22447, which was remarkably up-regulated in CAFs, referred to LncRNA-CAF (Lnc-CAF) hereafter. Interleukin-33 (IL-33) was mainly located in the stroma and positively co-expressed with Lnc-CAF to elevate the expression of CAF markers (α-SMA, vimentin and N-cadherin) in fibroblasts. In a co-culture system, IL-33 knockdown impaired Lnc-CAF-mediated stromal fibroblast activation, leading to decreased proliferation of tumor cells. Mechanistically, Lnc-CAF up-regulated IL-33 levels and prevented p62-dependent autophagy–lysosome degradation of IL-33, which was independent of LncRNA-protein scaffold effects. Treatment with the autophagy inducer, rapamycin, impaired the proliferative effect of Lnc-CAF/IL-33 by promoting IL-33 degradation. In turn, tumor cells further increased Lnc-CAF levels in stromal fibroblasts via exosomal Lnc-CAF. In patients with OSCC, high Lnc-CAF/IL-33 expression correlated with high TNM stage (n = 140). Moreover, high Lnc-CAF expression predicted poor prognosis. In vivo, Lnc-CAF knockdown restricted tumor growth and was associated with decreased Ki-67 expression and α-SMA+ CAF in the stroma. In conclusion, we identified a stromal lncRNA signature, which reprograms NFs to CAFs via Lnc-CAF/IL-33 and promotes OSCC development.

1 January 2009 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
YHYali Hu
Yali Hu
PLPengfei Li
Pengfei Li
SHSha Hao
Sha Hao
LLLiu Liu
Liu Liu
JZJunli Zhao
Junli Zhao
YHYayi Hou
Yayi Hou
The pathogenesis of pre-eclampsia (PE) is incompletely understood. The placenta is considered to play a key role in this disease. Recent research showed that many microRNAs (miRNAs) are expressed in human placenta. Our aim in this study was to determine differential expression of miRNAs in placenta with severe PE, and normal placenta. Differential expression of miRNAs in placenta (four severe PE and a control group of four normal pregnant women) was first screened using microarray analysis. Following this, some differential miRNAs were selected and validated using real-time quantitative reverse transcription-polymerase chain reaction in placenta from women with severe PE (n=24), and a healthy control group (n=26). We found the following miRNAs were significantly increased in placenta from women with severe PE: miR-16, miR-29b, miR-195, miR-26b, miR-181a, miR-335 and miR-222. Gene ontology analysis of the target genes revealed enrichment for specific biological process categories, i.e., regulation of cellular physiological process including miR-16, miR-29b, miR-195, miR-26b and miR-335, and signal transduction including miR-181a and miR-222. These different miRNAs may play an important role in pathogenesis of PE and may become diagnostic markers for PE.